Malmö-based biotech company Cyxone develops new therapies for the treatment of autoimmune diseases, such as rheumatoid arthritis with the phase IIb candidate Rabeximod and multiple sclerosis with drug candidate T20K. Carl-Magnus Högerkorp, recently appointed permanent CEO of Cyxone, visited BioStock’s studio to tell us more about the current state and the prospects of the pipeline.
Watch the interview with Cyxone’s CEO Carl-Magnus Högerkorp in the link below.
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.